Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with eligible genetic alterations. Ziftomenib is a type of therapy known to target the menin pathway in cancer cells. This protocol has 2 separate studies that will investigate the benefits and risks of adding ziftomenib to standard-of-care (SOC) AML treatments in patients with certain genetic mutations who have not received any treatment for their AML. In the first study, the Nonintensive Therapy Study, older patients or those with serious medical problems will receive the SOC therapies venetoclax (ven) and azacitidine (aza), plus either ziftomenib or a placebo. In the second study, the Intensive Therapy Study, medically fit patients will receive (a) the SOC therapies cytarabine and daunorubicin, plus either ziftomenib or a placebo during a first treatment phase called induction, (b) cytarabine plus either ziftomenib or a placebo during a second treatment phase called consolidation, and (c) ziftomenib or a placebo during a third treatment phase called maintenance. The physician will determine which study is the appropriate treatment for the patient, but neither the patient nor their physician will know whether the patient has been assigned to receive ziftomenib or a placebo. This design is called "double-blinded".
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek powyżej 18 lat.
- •Diagnoza ostrej białaczki szpikowej (AML).
- •Dobry ogólny stan zdrowia pozwalający na leczenie.
- •Wystarczająca praca wątroby i nerek.
- •Dla kobiet i mężczyzn: konieczność stosowania antykoncepcji podczas i po leczeniu.
✗ Disqualifies
- •Wcześniejsze leczenie ostrej białaczki szpikowej (poza lekami doraźnymi).
- •Diagnoza innego rodzaju białaczki (np. ostra białaczka promielocytowa) lub innych chorób nowotworowych w trakcie badania.
- •Stwierdzona obecność określonych mutacji genetycznych (np. BCR-ABL).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- June 29, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (82)
Banner MD Anderson Cancer Center
Gilbert, United States
University of California, Fresno
Clovis, United States
University of California, San Diego
La Jolla, United States
Cedars-Sinai Medical Center
Los Angeles, United States
University of California, Los Angeles
Los Angeles, United States
University of California, Irvine
Orange, United States
University of Colorado
Aurora, United States
Colorado Blood Cancer Institute
Denver, United States
Hartford HealthCare Cancer Institute
Hartford, United States
Yale University School of Medicine
New Haven, United States
University of Miami
Miami, United States
Moffitt Cancer Center & Research Institute
Tampa, United States
University of Iowa
Iowa City, United States
University of Kentucky
Lexington, United States
University of Massachusetts
Worcester, United States
University of Michigan
Ann Arbor, United States
Wayne State University School of Medicine
Detroit, United States
University of Minnesota
Minneapolis, United States
Rutgers Biomedical and Health Sciences
New Brunswick, United States
University of New Mexico
Albuquerque, United States
State University of New York at Buffalo
Buffalo, United States
Icahn School of Medicine at Mount Sinai
New York, United States
Columbia University
New York, United States
Weill Cornell Medical Center
New York, United States
University of North Carolina, Chapel Hill
Chapel Hill, United States
Duke University Medical Center
Durham, United States
Ohio State University
Columbus, United States
Willamette Valley Cancer Institute
Eugene, United States
University of Pennsylvania
Philadelphia, United States
Baptist Clinical Research Institute
Memphis, United States
Tennessee Oncology
Nashville, United States
TriStar Centennial Medical Center
Nashville, United States
Texas Oncology-Austin Midtown
Austin, United States
Texas Oncology-Presbyterian Cancer Center
Dallas, United States
University of Texas
Houston, United States
Texas Oncology - San Antonio Medical Center
San Antonio, United States
University of Vermont Medical Center
Burlington, United States
University of Virginia School of Medicine
Charlottesville, United States
Virginia Cancer Specialists
Manassas, United States
WVU Medicine Wheeling Hospital
Wheeling, United States
University of Wisconsin
Madison, United States
Froedtert & Medical College of Wisconsin
Milwaukee, United States
Calvary Mater Newcastle
Waratah, Australia
Fakultni Nemocnice Ostrava
Ostrava-Poruba, Czechia
Fakultní Nemocnice Královské Vinohrady
Prague, Czechia
Centre Hospitalier Universitaire Estaing - Clermont-Ferrand
Clermont-Ferrand, France
Hôpital Lyon Sud
Pierre-Bénite, France
Centre Hospitalier Universitaire de Saint Etienne
Saint-Priest-en-Jarez, France
Groupe Hospitalier de la Region de Mulhouse et Sud Alsace Hôpital Emile Muller
Mulhouse, France
Centre Hospitalier Régional et Universitaire de Nancy Hôpitaux de Brabois
Vandœuvre-lès-Nancy, France
Centre Hospitalier Universitaire de Nantes
Nantes, France
Centre Hospitalier Universitaire de Bordeaux
Pessac, France
Centre Hospitalier de Béziers
Béziers, France
Hôpital Universitaire Henri Mondor
Créteil, France
Hôpital Avicenne
Bobigny, France
Hôpital Saint Louis
Paris, France
Helios Klinikum Bad Saarow
Bad Saarow, Germany
Attikon University General Hospital of Athens
Chaïdári, Greece
University General Hospital of Alexandroupoli
Alexandroupoli, Greece
L'IRCCS Azienda Ospedaliero - Universitaria di Bologna
Bologna, Italy
Azienda Sanitaria Territoriale di Ascoli Piceno
Ascoli Piceno, Italy
Azienda Ospedaliero-Universitaria
Perugia, Italy
Baguio General Hospital and Medical Center
Baguio City, Philippines
Hospital de Braga, Centro Clínico Académico de Braga
Braga, Portugal
Anam Hospital Korea University
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Dong-A University Hospital
Busan, South Korea
Pusan National University Hospital
Busan, South Korea
Chungnam National University Daejeon Hospital
Daejeon, South Korea
Chonnam National University Hwasun Hospital
Hwasun, South Korea
Ulsan University Hospital
Ulsan, South Korea
University Hospital Virgen Del Rocio S.L.
Seville, Spain
Hospital Clinico Universitario Lozano Blesa
Zaragoza, Spain
Hospital Universitario De Burgos
Burgos, Spain
Hospital General Universitario de Albacete
Albacete, Spain
Hospital Universitario Infanta Leonor
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Clinico Universitario de Valencia
Valencia, Spain
Hospital Universitario Y Politecnico La Fe
Valencia, Spain
Chang Bing Show Chwan Memorial Hospital
Lugang, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Trial contact
Kura Medical Information
Contact information from ClinicalTrials.gov. Contact in English.
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/3/2026.